Navigation Links
Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon

Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities and clinical trials, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. Government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

CONTACT: Jerry Parrott, Vice President, Corporate Communications,+1-301-315-2777, Kate de Santis, Director, Inv
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:8/21/2014)... , Aug. 21, 2014   Memorial Hermann Health System ... Center today announced a new partnership to provide a ... community breast care centers in the greater Houston ... Anderson will become the exclusive provider of professional breast radiology ... located in Memorial City, The Woodlands , ...
(Date:8/21/2014)... 21, 2014 Nektar Therapeutics (NASDAQ: ... announced positive results from its Phase 3 pivotal ... half-life recombinant factor VIII (rFVIII) treatment for hemophilia ... met its primary endpoint in reducing annualized bleed ... the on-demand arm. Top-line results from ...
(Date:8/21/2014)... The spinal column is one of the most delicate and ... from the brain through the column control many key functions ... here can be life altering, and leave the victim in ... body. Though back injury and disease can have an intensely ... available to make things better than ever before. Laser ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2
... 6, 2011 NeuroSigma, Inc., a Los Angeles-based ... a notice of award for an NIH Small ... the National Institute of Neurological Disorders and Stroke ... trigeminal nerve stimulation (eTNS™) therapy for the treatment ...
... NEW YORK, Sept. 6, 2011 ... research report is available in its ... Vaccines - Cell Culture Technology Gradually ... http://www.reportlinker.com/p0610894/Manufacturing-of-Vaccines---Cell-Culture-Technology-Gradually-Replacing-Egg-Based-Manufacturing.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication Manufacturing ...
Cached Medicine Technology:NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy 2Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 2Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 3Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 4Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 5Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 6Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 7
(Date:8/22/2014)... need surgery for facial pain caused by trigeminal neuralgia, ... reports a study in the September issue of ... Congress of Neurological Surgeons . The journal is published ... of Wolters Kluwer Health . , Percutaneous stereotaxic ... cost than other types of surgical treatments for trigeminal ...
(Date:8/22/2014)... Key West Health & Beauty’s ( ... much anticipated study results of the 12 best and ... an accompanying infographic on their website. It appears that ... major impact on the skin and contribute to many ... When asked how they determined the results, founder and ...
(Date:8/22/2014)... According to the new research ... Global Trends & Forecast to 2019" defines and ... forecast of the market value. The isocyanate material ... 2019, at a significant CAGR from 2014 to ... 44 figures spread through 286 pages and in-depth ...
(Date:8/22/2014)... 22, 2014 Braverman Eye Center is ... Lauderdale at the most affordable fee. They are on ... their advanced Lasik treatments. LASIK is a highly successful ... Eye Center has been delivering successful LASIK solutions to ... glasses-free and contact lenses-free life with the help of ...
(Date:8/22/2014)... A new study finds a wide range of ... related to key environmental exposuresin children with Crohn,s disease (CD), ... of the Crohn,s & Colitis Foundation of America ... & Wilkins , a part of Wolters Kluwer Health ... alterations of DNA in several regions of the genome in ...
Breaking Medicine News(10 mins):Health News:More common procedures for painful facial tics carry high costs, reports study in Neurosurgery 2Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 3Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 4Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Study shows epigenetic changes in children with Crohn's disease 2
... associated protein-1 (TRAP-1) may prevent cancer cell death. The ... as a Novel Molecular Target in Localized and Metastatic Prostate ... American Journal of Pathology . Prostate cancer is the ... cause of cancer deaths among men in the United States, ...
... are not as stringent as with new medications , TUESDAY, ... Administration may not be as stringent in evaluating devices as ... report in the Dec. 23/30 issue of the Journal ... often sails through based on studies that are not randomized ...
... stick to your workout routine, even in foul weather , ... chill on even the most enthusiastic exerciser,s plans. It,s hard ... sidestep icy patches. And who wants to go to the ... windshield first? , But sticking to your exercise program throughout ...
... have replaced the street as easy source of medications, experts ... death of pop star Michael Jackson in 2009 drew new ... States. , And with that attention has come acknowledgment ... five teenagers and adults -- about 50 million Americans -- ...
... the lab, expert says , TUESDAY, Dec. 29 (HealthDay ... cause some germs to develop resistance to antibiotics, new ... outside of the laboratory and they don,t suggest that ... "It is OK to use disinfectants. Just don,t misuse ...
... Texas, Dec. 29 Top marketing representatives ... Global Hotel Alliance brand members recently hosted a unique "Lasso ... The luxury hotel brands from across the world readily joined forces ... GHA associate who succumbed to lymphoma cancer in May. ...
Cached Medicine News:Health News:The cancer 'TRAP' 2Health News:Study Questions FDA Approvals of Cardiac Devices 2Health News:Study Questions FDA Approvals of Cardiac Devices 3Health News:Study Questions FDA Approvals of Cardiac Devices 4Health News: Winter Exercise Can Lift Your Spirits 2Health News:In U.S., Prescription Drug Abuse Is Growing 2Health News:In U.S., Prescription Drug Abuse Is Growing 3Health News:In U.S., Prescription Drug Abuse Is Growing 4Health News:Disinfectant Misuse Might Help Germs Resist Antibiotics 2Health News:Disinfectant Misuse Might Help Germs Resist Antibiotics 3Health News:Omni Hotels & Resorts and Global Hotel Alliance Partner for Charity 2Health News:Omni Hotels & Resorts and Global Hotel Alliance Partner for Charity 3